Amedisys Reports Third Quarter 2018 Financial Results and Updates 2018 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Amedisys (AMED) PT Raised to $126 at RBC Capital
October 31, 2018 6:59 AM EDTRBC Capital analyst Frank Morgan raised the price target on Amedisys (NASDAQ: AMED) to $126.00 (from $115.00) while maintaining an Outperform rating.
Morgan noted a strong Q3, with momentum in 2019.
... MoreAmedisys (AMED) Tops Q3 EPS by 18c, Raises FY Guidance
October 29, 2018 5:02 PM EDTAmedisys (NASDAQ: AMED) reported Q3 EPS of $0.95, $0.18 better than the analyst estimate of $0.77. Revenue for the quarter came in at $417.3 million versus the consensus estimate of $411.2 million.
GUIDANCE:
Amedisys sees FY2018 EPS of $3.54-$3.60, versus the consensus of $3.40. Amedisys sees... More
